Dr. Per-Olof Andersson, New Executive Director for the R&D Area in Almirall

Barcelona, 26 January 2006.- Almirall announces the appointment of Per-Olof Andersson as the new Executive Director for the R&D area.Dr. Andersson, who will be reporting directly to the President-CEO, has joined Almirall in order to become a part of the company’s new strategic challenges for the future.

With a doctorate in Medicine from the University of Lund, Sweden, Dr. Andersson has occupied a variety of positions of responsibility in the pharmaceutical industry, the most recent being Vice President Clinical R&D in Pfizer Japan. He has also worked in multinational companies such as Pharmacia as well as Pfizer both in Europe and in the USA, thus obtaining broad professional international experience.

Dr. Andersson has extensive experience in the R&D sector in the areas of Discovery, Exploratory Development and Clinical R&D.

Almirall, a leading company committed to health

Almirall is a consolidated international pharmaceutical company that researches, develops and commercialises own R&D and licensed specialities with the aim of improving health and quality of life. The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD, psoriasis and rheumatoid arthritis.

Almirall is currently present in around 100 countries with own products and licensed products from other prestigious companies.The company is strengthening its direct presence in Europe and Latin America via affiliates.